Cancer Immunotherapy-An Overview.

Cancer remains a daunting task for clinicians and scientists. Many scientists across the globe are toiling in their labs to find an effective and safe treatment modality for cancer. Although significant stride has been achieved in the field of cancer treatment, and millions of precious lives have been saved using available therapeutic strategies, viz. chemotherapy, radiation therapy, biologics and surgical intervention. However, the search for the panacea for cancer is still not over, and new dimensions are being constantly explored. Maneuvering the immune system for controlling and treating cancer is a new fascinating field, and rigorous researches are underway. The importance of anticancer immunity as a promising treatment approach has been recognised even by the Nobel Prize Authority and James P. Allison and Tasuku Honjo were jointly awarded the 2018 Nobel Prize in Physiology or Medicine for their revolutionary research in cancer immunotherapy. This chapter discusses the different aspects of immune system response vis a vis cancer development and strategies to manipulate the immune system through prebiotics and postbiotics to control and cure the different types of cancer. Prebiotics and postbiotics are being explored extensively for their role in modifying disease progression and control of cancer. Prebiotics and postbiotics are considered safe alternatives to manipulate the immune system in order to get therapeutic benefits for cancer.

Combining Innate Immunity With Radiation Therapy for Cancer Treatment

EP06.01-003 Impact of COVID-19 on Lung Cancer Patients; The Patients’ Perspective

Cancer is the leading cause of deaths worldwide due to their complexity, diversity, risk of reoccurrence, and limited therapeutic options, which are further hindered by the potential side effects. Moreover, the limited potential of detection tools lead to the severity of different types of cancers. An early detection definitely increases the chances of recovery and survival rates. To this end, microbiome, representing the collection of all microorganisms and their genes that live on and inside the body, is recognized as an important player in the diagnosis of different types of cancers. Different well-studied human microbiomes mainly comprising of different bacteria have potential etiological roles in carcinogenesis and/or modulating the individual response to therapies. This chapter provides the current knowledge on different healthy microbiome of different parts of the body and how it is altered during the development of different types of cancers. Specifically, it discusses the microbiome of intestine, oral, lung, vagina, gut, uterus, skin, etc. and their role as biomarkers for the detection of colorectal, pancreatic, liver, breast, lung, cervical, oral and oropharyngeal, and skin cancers. We also provided the current knowledge of microbiota-based therapeutics and management of different types of cancers through different therapies.KeywordsMicrobiotaCancer biomarkersGastrointestinal microbiomeSkin microbiomeCancer management

Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy

Recent advances in basic immunology have revealed impressive breakthroughs in the field of cancer immunotherapy, inspiring oncologists to translate this knowledge to the treatment of different types of cancers. However, several hurdles limit the efficiency of immunotherapy in increasing the overall survival of patients (Fig. 31.1). These hurdles rank from practical and economic issues such as feasibility and cost-effectiveness of immunotherapy and design of the clinical trials to the several immunological hurdles. In the immunological hurdles, tumor cells possess several mechanisms to evade the immune system response. A combination of factors such as the production of inhibitory cytokines and soluble factors such as the expression of inhibitory markers and conversion of cellular infiltrates into the tolerizing cells contribute to evasion of the immune system. Moreover, some tumor cells acquire apoptosis resistance through different strategies, and some cause the immune system to autoreact to host tissue. All these mechanisms inhibit tumor regression and the effectiveness of immunotherapy. Moreover, immunotherapy-related toxicities have proven to be a major issue in cancer immunotherapies, which required timely and properly management. Therefore, efforts for minimizing the side effects in parallel to maximizing the efficiency of immunotherapies are still warranted. In this chapter, we discuss the potential hurdles that confront cancer immunotherapy and the potential strategies to overcome these challenges and achieve a successful immune response against tumor.

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.

The cost of hope: Doctors weigh the benefits of new drugs against sky-high costs

FDA Approves Avastin in Combination with Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer

Cancer Immunotherapies and Humanized Mouse Drug Testing Platforms

Resistance to Checkpoint Inhibition in Cancer Immunotherapy

Immunotherapy (cancer immunotherapy) is a promising approach to cancer treatment that recognizes and destroys cancer cells by employing immune-related components or by directing the immune system. Between 2017 and 2020, the R&D pipeline for cancer immunotherapies increased by 233%. Immunotherapy can be broadly divided into five broad categories and is suitable for 20 different types of cancer. With the introduction of immune checkpoint inhibitors and CAR-T cell therapies, this approach has revolutionized the way of cancer treatment, even treating some patients with advanced cancers, while not all cancer types respond well to this approach. The effectiveness of immunotherapy as a stand-alone treatment is often constrained by tumor heterogeneity, immune evasion, and resistance mechanisms. To address these issues, immunotherapy is being investigated in combination with other traditional treatment modalities such as radiotherapy, chemotherapy and targeted drugs as a way to improve treatment outcomes. This review explores the rationale behind these combination therapies and discusses the potential of these combined therapies to improve patient survival and quality of life.

The detection of cancerous cells by the immune system elicits spontaneous antitumour im-mune responses. Still, during their progression, tumours acquire characteristics that enable them to escape immune surveillance. Cancer immunotherapy aims to reverse tumour im-mune evasion by activating and directing the immune system against transformed tumour cells. However, the tumours’ intrinsic resistance mechanisms limit the success of many im-munotherapeutic approaches. The functionally and morphologically abnormal tumour vascu-lature forms a physical barrier and prevents the entry of tumour-reactive immune effector cells, while the immunosuppressive tumour microenvironment impairs their function. To block tumour immune evasion, therapeutic strategies are being developed that combine cancer immunotherapy with treatment modalities, such as radiotherapy, that reprogram the tumour microenvironment to increase treatment efficacies and improve clinical outcome. In various preclinical models radiotherapy was shown to enhance the efficacy of adoptive T cell therapy. Our group showed that in the RIP1-TAg5 mouse model of spontaneous insulinoma, the transfer of in vitro-activated tumour-specific T cells induces T cell infiltration and pro-motes long-term survival only in combination with neoadjuvant local low dose irradiation (LDI). These treatment effects were mediated by iNOS+ macrophages. In this thesis, we investigated the mechanisms underlying the improved T cell infiltration and prolonged survival upon combination therapy with adoptive T cell transfer and local LDI. We demonstrate that combination therapy leads to a normalization of the aberrant tumour vas-culature and endothelial activation, an increase in intratumoural macrophages, a reduction of intratumoural myeloid derived suppressor cells and, most importantly, to tumour regres-sion. These findings suggest that this treatment inhibits tumour immune suppression but also facilitates immune effector cell infiltration through the normalization of the tumour vasculature, finally leading to tumour immune rejection. Inhibition of the inducible nitric oxide (NO) synthase (iNOS) revealed that these effects largely depend on its activity. Of note, the stimulation of human endothelial cells with low doses of the NO donor DETA NONOate activates the endothelial cells to upregulate adhesion molecules, indicating that in response to the combination therapy, iNOS-derived NO directly activates tumour endothelial cells, thereby promoting T cell infiltration and tumour immune rejection. Moreover, adoptive transfer of low dose irradiated peritoneal macrophages into unirradiat-ed RIP1-TAg5 mice prior to adoptive T cell transfer resulted in effects corresponding to the combination treatment, which highlights the role of macrophages in this mechanism. Whole transcriptome analysis of the irradiated peritoneal macrophages revealed that LDI causes gene expression and functional changes in these cells. Specifically, LDI activated interferon signalling and induced the upregulation of interferon regulated genes. This effect is likely due to the detection of danger signals released from damaged cells, which primes macro-phages and induces a shift in their polarization state. Signal transduction and amplification of interferon responses is mediated by interferon regulatory factors like IRF7. These transcription factors induce the expression of proinflammatory genes such as Nos2. Irf7 but also Nos2 and various proinflammatory genes like tumour necrosis factor (Tnf) were upregulated in response to LDI. Since NO and TNF-α are mediators of endothelial activation, this finding represents the link between LDI and macrophage-mediated activation of the tumour endothelium. In conclusion, the presented thesis demonstrates that macrophages with proinflammatory phenotypes are required for the activation of tumour endothelial cells, which in turn is criti-cal for the infiltration of immune effector cells and, thereby, for tumour immune destruction. Therefore these findings are of great importance for future immunotherapeutic approaches in the treatment of cancer patients.

A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer

We have analyzed gene expression in different normal human tissues and different types of solid cancers derived from these tissues. The cancers analyzed include brain (astrocytoma and glioblastoma), breast, colon, endometrium, kidney, liver, lung, ovary, prostate, skin, and thyroid cancers. Comparing gene expression in each normal tissue to 12 other normal tissues, we identified 4,917 tissue-selective genes that were selectively expressed in different normal tissues. We also identified 2,929 genes that are overexpressed at least 4-fold in the cancers compared with the normal tissue from which these cancers were derived. The overlap between these two gene groups identified 1,340 tissue-selective genes that are overexpressed in cancers. Different types of cancers, including different brain cancers arising from the same lineage, showed differences in the tissue-selective genes they overexpressed. Melanomas overexpressed the highest number of brain-selective genes and this may contribute to melanoma metastasis to the brain. Of all of the genes with tissue-selective expression, those selectively expressed in testis showed the highest frequency of genes that are overexpressed in at least two types of cancer. However, colon and prostate cancers did not overexpress any testis-selective gene. Nearly all of the genes with tissue-selective expression that are overexpressed in cancers showed selective expression in tissues different from the cancers' tissue of origin. Cancers aberrantly expressing such genes may acquire phenotypic alterations that contribute to cancer cell viability, growth, and metastasis.